The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations]

Background: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharma...

Full description

Bibliographic Details
Main Authors: Rana M. ElDash, Mohamed A. Raslan, Sara M. Shaheen, Nagwa Ali Sabri
Format: Article
Language:English
Published: F1000 Research Ltd 2021-04-01
Series:F1000Research
Online Access:https://f1000research.com/articles/10-321/v1